Abstract
A beneficial effect of the combination of quinupristin-dalfopristin and vancomycin was observed against two methicillin-resistant strains of Staphylococcus aureus harboring or not harboring the ermC gene, which codes for constitutive macrolide, lincosamide, and streptogramin B resistance. The beneficial effect was observed in time-kill studies, in which the drugs were used at inhibitory concentrations, and in a rabbit model of endocarditis, in which the combination was highly bactericidal and more active than monotherapies.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use*
-
Culture Media
-
Drug Resistance
-
Drug Therapy, Combination / pharmacology*
-
Drug Therapy, Combination / therapeutic use*
-
Endocarditis, Bacterial / drug therapy*
-
Endocarditis, Bacterial / microbiology
-
Lincosamides
-
Macrolides*
-
Methicillin Resistance
-
Microbial Sensitivity Tests
-
Rabbits
-
Staphylococcus aureus / drug effects*
-
Streptogramin B / pharmacology
-
Time Factors
-
Vancomycin / pharmacology*
-
Vancomycin / therapeutic use*
-
Virginiamycin / pharmacology*
-
Virginiamycin / therapeutic use*
Substances
-
Anti-Bacterial Agents
-
Culture Media
-
Lincosamides
-
Macrolides
-
Virginiamycin
-
quinupristin-dalfopristin
-
Streptogramin B
-
Vancomycin